NCT00098514View on ClinicalTrials.gov

Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

March 31, 2007

Study Completion Date

May 31, 2011

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

talotrexin ammonium

Trial Locations (1)

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT00098514 - Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors | Biotech Hunter | Biotech Hunter